RESEARCH ARTICLE


Efficacy of Pimecrolimus in Fox-Fordyce Disease



Arani Chandrakumar1, Nick Francis2, Nilesh Morar*, 1
1 Department of Dermatology, Chelsea & Westminster Hospital, London, UK
2 Department of Histopathology, Imperial College Healthcare, NHS Trust, UK


Article Metrics

CrossRef Citations:
0
Total Statistics:

Full-Text HTML Views: 555
Abstract HTML Views: 1478
PDF Downloads: 1261
Total Views/Downloads: 3294
Unique Statistics:

Full-Text HTML Views: 348
Abstract HTML Views: 907
PDF Downloads: 844
Total Views/Downloads: 2099



Creative Commons License
© 2010 Chandrakumar et al.

open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

* Address correspondence to this author at the Department of Dermatology, Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK; E-mail: nilesh.morar@chelwest.nhs.uk


Abstract

Fox-Fordyce disease (FFD) or 'apocrine miliaria' is a rare benign skin condition characterized by obstruction of the apocrine sweat gland. Treatment is generally unsatisfactory. A 15-year-old girl presented with intensely pruritic lesions on her axillae, chest and groin. Histology from an axillary skin biopsy confirmed FFD. The patient was commenced on pimecrolimus cream twice daily for three months and then once daily for a further three months. After a month she had marked improvement of her symptoms. By three months, the papules had flattened. The lesions remained healed at follow up nine months after completing therapy. Pimecrolimus is a safe and easy to use option and we suggest that it may be considered as first-line therapy for FFD.

Keywords: Fox-Fordyce disease, apocrine miliaria, pimecrolimus, Elidel, treatment.